CRIS Current Research Information System

FAROLFI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.423
NA - Nord America 1.955
EU - Europa 849
SA - Sud America 150
Continente sconosciuto - Info sul continente non disponibili 138
AF - Africa 87
OC - Oceania 4
Totale 5.606
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.880
SG - Singapore 768
VN - Vietnam 547
CN - Cina 526
IT - Italia 228
HK - Hong Kong 226
BD - Bangladesh 120
DE - Germania 112
BR - Brasile 104
GB - Regno Unito 83
FR - Francia 79
SE - Svezia 74
NL - Olanda 57
KR - Corea 54
IN - India 50
FI - Finlandia 42
CA - Canada 35
CI - Costa d'Avorio 33
IE - Irlanda 32
RU - Federazione Russa 31
JP - Giappone 26
AT - Austria 19
ID - Indonesia 19
AR - Argentina 18
SC - Seychelles 16
CH - Svizzera 14
ES - Italia 14
TH - Thailandia 14
BG - Bulgaria 13
BE - Belgio 12
PH - Filippine 12
UA - Ucraina 12
MX - Messico 11
IQ - Iraq 9
JM - Giamaica 9
TG - Togo 9
ZA - Sudafrica 9
JO - Giordania 7
TW - Taiwan 7
VE - Venezuela 7
CL - Cile 6
CO - Colombia 6
EC - Ecuador 6
TT - Trinidad e Tobago 6
SA - Arabia Saudita 5
UZ - Uzbekistan 5
AU - Australia 4
DZ - Algeria 4
MY - Malesia 4
PK - Pakistan 4
TR - Turchia 4
CZ - Repubblica Ceca 3
EE - Estonia 3
GR - Grecia 3
IR - Iran 3
LT - Lituania 3
NI - Nicaragua 3
PL - Polonia 3
TN - Tunisia 3
BB - Barbados 2
CR - Costa Rica 2
HN - Honduras 2
IL - Israele 2
KE - Kenya 2
KW - Kuwait 2
LB - Libano 2
LY - Libia 2
NG - Nigeria 2
NP - Nepal 2
PE - Perù 2
PR - Porto Rico 2
PT - Portogallo 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GA - Gabon 1
HR - Croazia 1
HU - Ungheria 1
KG - Kirghizistan 1
KZ - Kazakistan 1
MA - Marocco 1
MD - Moldavia 1
MU - Mauritius 1
PA - Panama 1
PY - Paraguay 1
QA - Qatar 1
TJ - Tagikistan 1
TZ - Tanzania 1
Totale 5.468
Salva come PNG Salva come JPEG
Città #
Singapore 538
San Jose 261
Ashburn 243
Hong Kong 208
Ho Chi Minh City 153
Hanoi 146
Santa Clara 143
Hefei 125
Council Bluffs 114
Beijing 77
Chandler 70
Boardman 64
Southend 55
Los Angeles 50
Seoul 47
Fairfield 45
Helsinki 39
Lauterbourg 38
New York 36
Dallas 34
Abidjan 33
Ann Arbor 32
Dublin 32
Buffalo 30
Houston 26
Princeton 26
Rome 25
Chicago 23
Da Nang 23
Seattle 22
Frankfurt am Main 21
Wilmington 21
Bologna 19
Tokyo 19
Milan 18
Woodbridge 18
Cambridge 16
Haiphong 16
São Paulo 15
Bengaluru 14
Falkenstein 14
Munich 14
Nuremberg 14
Guangzhou 13
Jakarta 13
Redondo Beach 13
Sofia 13
Turin 13
Shanghai 12
Brooklyn 11
Bern 10
Bangkok 9
Brussels 9
Jacksonville 9
Lomé 9
Vienna 9
Can Tho 8
Denver 8
London 8
Phoenix 8
Shenzhen 8
Amman 7
Atlanta 7
Düsseldorf 7
Florence 7
Hangzhou 7
Hải Dương 7
Mexico City 7
Montreal 7
San Francisco 7
Shijiazhuang 7
Toronto 7
Berlin 6
Des Moines 6
Fort Worth 6
Genoa 6
Montescudo 6
Nanjing 6
Padova 6
Rach Gia 6
Rio de Janeiro 6
Stockholm 6
Baghdad 5
Belo Horizonte 5
Boston 5
Casalecchio di Reno 5
Catania 5
Changsha 5
Cleveland 5
Jinan 5
Modena 5
Philadelphia 5
Tashkent 5
Tianjin 5
Verona 5
Westminster 5
Wuhan 5
Barcelona 4
Cincinnati 4
Dongguan 4
Totale 3.384
Salva come PNG Salva come JPEG
Nome #
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 211
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 196
Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ 191
Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients 179
Endometrioid Cancer Associated With Endometriosis: From the Seed and Soil Theory to Clinical Practice 175
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 160
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors 157
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 152
Early Detection of Cardiotoxicity in Chemotherapy-Treated Patients from Real-time 3D Echocardiography 151
Differences in biological features of breast cancer between Caucasian (Italian) and African (Tanzanian) populations. 146
Does the time between CT scan and chemotherapy increase the risk of acute adverse reactions to iodinated contrast media in cancer patients? 144
Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma 144
The interplay between inflammation, anti-angiogenic agents, and immune checkpoint inhibitors: Perspectives for renal cell cancer treatment 142
Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial 134
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients 133
Taxanes as a Risk Factor for Acute Adverse Reactions to Iodinated Contrast Media in Cancer Patients 124
Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors 122
Erratum to “Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life” [Eur J Cancer 69 (2016) 110–118] 121
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study 115
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer 113
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide 110
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide 104
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 95
Hydroxychloroquine as Prophylaxis for COVID-19: A Review 90
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer 89
Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial 89
Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial 84
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial 83
Trastuzumab-induced cardiotoxicity in early breast cancer patients: A retrospective study of possible risk and protective factors 77
Perspectives, Challenges, and Advances in Therapeutic Strategies for Gynecological Malignant Tumors 77
Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer 76
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? 75
Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia related to PARP inhibitor Maintenance Line in Real-world Ovarian Cancer Patients 73
Ipilimumab in advanced melanoma: Reports of long-lasting responses 72
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 71
Immunotherapy for prostate cancer: Where we are headed 71
Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions 69
Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy 68
Progress with palbociclib in breast cancer: Latest evidence and clinical considerations 67
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? 66
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature 66
Glutathione, glutathione disulfide, and S-glutathionylated proteins in cell cultures 65
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 65
Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy 64
ROLE OF HPV VACCINATION AFTER CARCINOMA IN SITU OF CERVIX UTERI (CIN) IN REAL-WORLD PATIENTS 62
Immune system and DNA repair defects in ovarian cancer: Implications for locoregional approaches 60
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer 60
Palbociclib (PD 0332991): Targeting the cell cycle machinery in breast cancer 60
Immune-checkpoint inhibitors and the importance of concomitant medications: focus on antibiotics 59
Bevacizumab as maintenance treatment in patients with ovarian cancer: Wait for BRCA testing 58
Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients 56
Hormonal receptor, human epidermal growth factor receptor-2, and ki67 discordance between primary breast cancer and paired metastases: Clinical impact 56
Paraneoplastic hypocalcemia-induced heart failure in advanced breast cancer: A case report and literature review 52
Psychosocial issues in long-term survivors of testicular cancer 45
Metastatic bone disease in the era of bone-targeted therapy: Clinical impact 44
Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer 35
Sorafenib for the treatment of breast cancer 33
Artificial intelligence for predicting pathological complete response to neoadjuvant therapy in triple-negative breast cancer: A systematic review and meta-analysis 29
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma 19
null 2
Totale 5.606
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.240
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.240
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022187 0 0 5 17 15 10 10 16 9 24 40 41
2022/2023283 23 37 8 37 20 24 10 12 66 7 16 23
2023/2024166 11 13 12 2 5 18 6 4 70 3 16 6
2024/20251.184 67 160 109 111 181 70 39 39 13 81 46 268
2025/20262.988 257 250 199 206 316 88 343 213 538 233 179 166
2026/2027517 94 174 249 0 0 0 0 0 0 0 0 0
Totale 5.606